PIRACETAM 800MG, CITICOLINE 500MG TABLETS are a dual-component solid oral formulation containing piracetam and citicoline at defined strengths of 800 mg and 500 mg respectively. The relatively high combined active load makes powder handling, blend uniformity, compression performance, and tablet dimensions important considerations during formulation development. At the same time, the two active ingredients need to remain chemically and physically compatible throughout manufacturing and storage. For pharmaceutical companies developing a structured PCD Pharma Franchise portfolio, a controlled formulation approach helps support reproducible product quality.
The combined active quantity in this formulation represents a substantial proportion of the finished tablet, which can influence tablet weight, powder flow, compressibility, and excipient selection. Formulation development therefore begins with characterization of both active ingredients and assessment of their physical properties.
Parameters such as particle size, bulk density, moisture content, flowability, and compressibility can be studied before selecting the final excipient system. Suitable diluents, binders, disintegrants, glidants, and lubricants may be incorporated according to the selected manufacturing process.
Compatibility studies can help establish whether piracetam and citicoline remain stable when combined with one another and with the selected excipients. This provides a basis for developing a formulation that remains consistent throughout processing and storage.
Because both active ingredients are present at relatively high quantities, powder flow and mixing behaviour are important manufacturing parameters. Differences in particle size or density can lead to segregation if material handling and blending are not properly controlled.
Depending on the formulation design, the active ingredients and excipients may undergo sieving, milling, premixing, or granulation before the final compression blend is prepared. The objective is to establish a powder mass with predictable flow and consistent distribution.
The blending sequence can be particularly important when combining materials with different physical characteristics. Blender load, mixing time, rotation speed, and order of addition are established during development and subsequently controlled during commercial production.
Samples may be collected from multiple locations within the blender to assess the uniformity of both piracetam and citicoline before compression.
After the final blend meets its predetermined specifications, it is transferred to the tablet compression stage. The high active load requires appropriate tooling and machine settings to produce tablets with acceptable dimensions and mechanical strength.
Compression force, feeder performance, turret speed, and dwell time can influence tablet hardness, thickness, friability, and weight variation. In-process monitoring allows these parameters to be adjusted within the validated operating range.
The finished tablets should possess adequate mechanical integrity to withstand coating, packaging, transportation, and routine handling. At the same time, the formulation must maintain appropriate disintegration and release characteristics.
Where film coating is incorporated, coating parameters such as spray rate, inlet temperature, pan speed, drying conditions, and coating weight gain are controlled to achieve a uniform surface.
Quality control for PIRACETAM 800MG, CITICOLINE 500MG TABLETS requires reliable analytical evaluation of both active components. Raw materials are tested against their approved specifications before being released for production.
Finished-product testing may include identification, assay, related substances, uniformity of dosage units, dissolution, friability, hardness, thickness, and other applicable quality parameters.
Analytical procedures should provide adequate specificity for evaluating piracetam and citicoline separately within the same dosage form. Appropriate sample preparation and validated analytical techniques help reduce the possibility of interference between the two components.
In-process testing of tablet weight and blend uniformity further supports batch consistency. All analytical and manufacturing observations are documented as part of the batch-release process.
Stability studies are conducted to determine whether PIRACETAM 800MG, CITICOLINE 500MG TABLETS maintain their required quality characteristics throughout the proposed shelf life. Evaluation may include assay, degradation products, dissolution, appearance, hardness, friability, and moisture-related changes.
Packaging selection should provide suitable protection against environmental exposure during storage and transportation. Blister packs, strips, or other pharmaceutical packaging formats may be evaluated depending on the stability profile of the formulation.
Packaging-development studies can assess moisture protection, seal integrity, material compatibility, and tablet protection during handling. Proper labeling, batch coding, and packaging inspection also contribute to product traceability.
The final packaging configuration is generally selected based on stability data and the physical characteristics of the finished tablets.
PIRACETAM 800MG, CITICOLINE 500MG TABLETS require coordinated control across raw-material characterization, powder processing, blending, compression, analytical testing, stability evaluation, and packaging. Because the formulation carries a comparatively high active load, maintaining consistent powder characteristics is especially important.
For pharmaceutical businesses, this dual-active tablet can form part of a broader PCD Pharma Franchise portfolio when supported by applicable regulatory requirements, standardized manufacturing procedures, and appropriate quality documentation. Reliable blend uniformity, controlled compression, validated analytical testing, suitable stability protection, and professional packaging provide a structured foundation for consistent pharmaceutical product development and distribution.
Piracetam 800mg + Citicoline 500mg Tablets with details on formulation, manufacturing, quality control, stability and pharmaceutical packaging.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech